US FDA Staff Weigh Urinary Effect of Valeant Pharmaceuticals International, GlaxoSmithKline Drug, Advisory Panel to Review Potiga on Wednesday

Reuters -- U.S. drug reviewers are concerned about urinary retention seen in some patients treated with an experimental epilepsy medicine from GlaxoSmithKline (GSK.L) and Valeant Pharmaceuticals (VRX.N), according to documents released on Monday.